Neeraj Sharma

Title: Neeraj Sharma: Innovating Cancer Therapy through CAR T Cell Technology

Introduction

Neeraj Sharma, an accomplished inventor based in South San Francisco, California, has made significant contributions to the field of immunotherapy. With a focus on innovative cancer treatments, his work is paving the way for more effective therapeutic options.

Latest Patents

Neeraj is credited with a patent for "ROR1 targeting chimeric antigen receptor." This groundbreaking invention encompasses polynucleotides that encode a chimeric polypeptide incorporating a c-Jun polypeptide, a ROR1-binding protein, and a truncated EGF receptor. The patent also covers T cells expressing CARs that include a ROR1-binding protein and exhibit overexpression of c-Jun, which has been shown to enhance their functionality by reducing or preventing exhaustion.

Career Highlights

Currently, Neeraj works at Lyell Immunopharma, Inc., where he continues to push the boundaries of immunotherapy. His innovative approaches are vital to improving CAR T cell therapies, which harness the body’s immune system to combat cancer more effectively.

Collaborations

Neeraj has had the privilege of collaborating with talented individuals such as Spencer Park and Queenie Vong. Together, they share a commitment to advancing medical science and improving patient outcomes through their respective expertise.

Conclusion

Neeraj Sharma stands out as a noteworthy inventor in the realm of cancer therapeutics. His patent on ROR1 targeting chimeric antigen receptors illustrates his dedication to finding solutions that could transform treatment paradigms for cancer patients. His ongoing work at Lyell Immunopharma, alongside his talented colleagues, promises to lead to more innovations in the future.